News

A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.

Data from a cohort of more than 8000 participants suggest that older adults with less optimal sleep duration might benefit from moderate napping for their cognitive functions.

The pediatric neurologist at Nationwide Children's Hospital talked about the year-over-year changes in day-to-day clinical practice of patients with epilepsy. [WATCH TIME: 4 minutes]

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]

After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change.

Results from the CIRCLES cohort demonstrated a significant association in relapse patterns and disease phenotype for patients with NMOSD who change treatment.

Over a 2-year treatment period, no clear effects of dimethyl fumarate were identified on clinical or MRI outcomes in patients with progressive multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Richard Williamson, MD, FAANS, a neurosurgeon at Allegheny Health Network, provided commentary on the explosion of technology in neurosurgery and how exoscopes ease the process.

The pediatric neurologist at Nationwide Children's Hospital spoke on several innovations and potential concerns in neurology clinicians should expect in 2023. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder, or NMOSD.

The executive director of Cure CMD discussed efforts being done to bring the stakeholder community together and improve the care for patients with congenital muscular dystrophies. [WATCH TIME: 4 minutes]

Li-Huei Tsai, PhD, director, the Picower Institute for Learning and Memory at Massachusetts Institute of Technology, discussed research results using gamma frequency sensory stimulation in Alzheimer disease.

Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 27, 2023.

The psychologist and professor in the department of rehabilitation medicine at the University of Washington talked about the benefits of a new initiative from the National MS Society focusing on mental health. [WATCH TIME: 4 minutes]

The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed ways to build off the ARISE study and the unanswered questions regarding radiologically isolated syndrome. [WATCH TIME: 3 minutes]

Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

The new criteria, inclusive of both pediatric and adult patients, advocates for testing for MOG-IgG in appropriate populations, and cautions against testing patients with clinical and radiological features typical of multiple sclerosis.

The vice dean for data science at Duke University School of Medicine spoke about the major disparities observed in models that assess stroke risk. [WATCH TIME: 4 minutes]

Data showed that slightly more than half of the patients with NMOSD visited at least 2 neurologists before receiving full diagnosis, and less than 30% reported they were aware of at least 1 nearby specialized NMOSD center.

The Abbott system previously earned approval for chronic pain in 2019, and adds another option for a patient population with no disease-modifying agents available for treatment.

After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.

Going forward, the company must provide safety and steady-state pharmacokinetic data on the 200 mg dose of IKT-148009, as well as continued measurement of visual acuity and examination of the cornea and lens.

In the combined double-blind and open-label extension periods, plasma neurofilament light levels were lower in those on teriflunomide and were prognostic of relapse or MRI activity.